Integra LifeSciences Holdings Corporation $IART Shares Bought by Inspire Investing LLC

Inspire Investing LLC grew its holdings in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 102.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,721 shares of the life sciences company’s stock after purchasing an additional 16,076 shares during the period. Inspire Investing LLC’s holdings in Integra LifeSciences were worth $389,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Compass Financial Group INC SD acquired a new stake in shares of Integra LifeSciences in the 2nd quarter worth approximately $172,000. State of Alaska Department of Revenue grew its holdings in shares of Integra LifeSciences by 51.5% in the 2nd quarter. State of Alaska Department of Revenue now owns 138,276 shares of the life sciences company’s stock worth $1,696,000 after acquiring an additional 47,012 shares during the period. Counterpoint Mutual Funds LLC acquired a new stake in shares of Integra LifeSciences in the 2nd quarter worth approximately $415,000. Wedge Capital Management L L P NC grew its holdings in shares of Integra LifeSciences by 1.2% in the 2nd quarter. Wedge Capital Management L L P NC now owns 70,114 shares of the life sciences company’s stock worth $860,000 after acquiring an additional 801 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in shares of Integra LifeSciences by 16.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 13,352 shares of the life sciences company’s stock worth $180,000 after acquiring an additional 1,927 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

Analysts Set New Price Targets

IART has been the topic of a number of research reports. Citigroup restated a “sell” rating and issued a $12.00 price target (up previously from $10.00) on shares of Integra LifeSciences in a report on Tuesday, October 7th. Weiss Ratings restated a “sell (d)” rating on shares of Integra LifeSciences in a report on Wednesday, October 8th. Finally, Truist Financial set a $15.00 price target on Integra LifeSciences and gave the stock a “hold” rating in a report on Wednesday. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $16.17.

Integra LifeSciences Price Performance

IART stock opened at $14.23 on Thursday. Integra LifeSciences Holdings Corporation has a 1 year low of $11.06 and a 1 year high of $27.13. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. The stock’s 50 day moving average price is $14.43 and its 200 day moving average price is $14.22. The firm has a market cap of $1.11 billion, a P/E ratio of -2.18 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The firm had revenue of $415.61 million for the quarter, compared to analyst estimates of $395.06 million. During the same quarter in the prior year, the company earned $0.63 EPS. Integra LifeSciences’s revenue was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, sell-side analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.